Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Hematopoietic stem cell transplantation should be offered to HIV+ patients with lymphoma

Key clinical point: Patients with lymphoma and HIV infection benefit from stem cell therapy, but with worse outcomes than non-HIV patients.

Major finding: Hematopoietic stem cell transplantation should be offered to HIV+ patients with lymphoma.

Study details: A total of 11,160 HIV+ vs. 349,607 HIV- patients were analyzed.

Disclosures: The authors reported that they had no conflicts of interest.

Commentary

"A retrospective cohort study using the National Cancer Database investigated outcomes in lymphoma patients with and without HIV infection from 2004-2015. Over 11,000 patients with lymphoma and HIV were compared to about 350,000 patients with lymphoma and without HIV. The most common lymphoma diagnosis in HIV patients was diffuse large B-cell lymphoma, a potentially curable disease which is usually fatal if untreated. As expected, HIV positive patients who received systemic treatment had better outcomes than those who were untreated. Female, non-Hispanic black, and Hispanic patients with HIV were less likely to receive systemic therapy than HIV patients who were male or of other racial/ethnic background. Future efforts should ensure that all HIV patients are offered treatment for lymphoma diagnoses if indicated."

Sarah Rutherford, MD

Assistant Professor of Medicine, Weill Cornell Medicine

Dr. Rutherford has no relevant conflicts of interest.

Citation:

Jayakrishnan TT et al. Clinical Lymphoma, Myeloma & Leukemia. 2020; doi.org/10.1016/j.clml.2020.06.003.